期刊文献+

屎肠球菌和粪肠球菌的耐药性分析 被引量:14

Antibiotic resistance study of Enterococcus faecium and Enterococcus faecalis
原文传递
导出
摘要 目的:了解屎肠球菌和粪肠球菌的耐药性,为临床提供治疗依据。方法:回顾性统计分析2005年1月~2009年9月间临床分离的屎肠球菌和粪肠球菌的分布与药敏试验结果。结果:检出屎肠球菌1286株和粪肠球菌1042株,均主要分离于尿液和痰液。屎肠球菌和粪肠球菌对利奈唑胺、万古霉素、替考拉宁的耐药率≤5.0%,对利福平耐药率≥74.3%。屎肠球菌对氨苄西林、青霉素和左旋氧氟沙星的耐药率≥92.3%,而粪肠球菌对相应药物的耐药率≤22.5%。屎肠球菌对高浓度庆大霉素和呋喃妥因的耐药率亦高于粪肠球菌。只有四环素的耐药率相反。结论:屎肠球菌对大多数抗菌药物的耐药率高于粪肠球菌,已发现万古霉素耐药肠球菌,应引起重视。 Objective:To investigate the anti-microbial resistance of Enterococcus faecium and Enterococcus faecalis to provide data for anti-infection therapy.Methods:We analyzed the clinical distribution and antibiotic resistance of E.faecium and E.faecalis which were collected from January 2005 to September 2009.Results:1286 isolates of E.faecium and 1042 isolates of E.faecalis were collected,and both of them mainly isolated from urine and sputamentum.Less than 5.0% of E.faecium and E.faecalis isolates were resistant to linezolid,vancomycin and teicoplanin,but more than 74.3% of them resistant to rifampicin.The resistance rate of E.faecium to ampicillin,penicillin and levofloxacin were higher than 92.3% and that of E.faecalis were lower than 22.5%.The resistant rate of E.faecium to gentamicin(high level)and nitrofurantoin was also higher than that of E.faecalis.Only the resistant rate to tetracycline was contrary.Conclusion:The resistance rate of E.faecium to most antibiotics is higher than that of E.faecalis.Vancomycin-resistant Enterococcus have been found,which should be paid close attention to.
出处 《中国卫生检验杂志》 CAS 2010年第5期1165-1166,共2页 Chinese Journal of Health Laboratory Technology
关键词 屎肠球菌 粪肠球菌 抗菌药物 耐药性 Enterococcus faecium Enterococcus faecalis Antibiotic Antimicrobial resistance
  • 相关文献

参考文献5

二级参考文献40

  • 1黄宪章,庞雪云,李强,陈冬梅,刘懿薇,田碧文,庄俊华.486株肠球菌菌型分布及耐药性研究[J].广东医学,2005,26(1):72-73. 被引量:5
  • 2瞿婷婷,须欣,陈亚岗,俞云松.肠球菌耐药性的研究进展[J].国外医学(流行病学.传染病学分册),2005,32(6):374-376. 被引量:9
  • 3武楠,杨祚升.肠球菌致病因子研究近况[J].中国感染控制杂志,2007,6(1):61-64. 被引量:8
  • 4Clinical and Laboratory Standards Institute. Performance standards for antimierobial susceptibility testing: Fifteenth Information Supplement[S]. 2007, M100-S17.
  • 5Sievert DM,Rudrik JT,Patel JB,et al. Vancomycin resistant Staphylococcus aureus in the United States, 2002-2006[J]. Clin Infect Dis,2008,46(5) :675-677.
  • 6Aligholi M, Emaneini M, Jabalameli F, et al. Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran[J]. Med Princ Pratt, 2008, 17(5) :432-434.
  • 7Saha B, Singh AK, Ghosh A,et al. Identification and characterization of a vaneomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia) [J]. J Med Microbiol, 2008, 57(Pt 1) :72-79.
  • 8Bell JM, Turnidge JD, Ballow CH,et al. Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific [J]. J Antimicrob Chemother,2003,51 (2) :339- 345.
  • 9Riehards MJ, Edwards JR, Culver DH, et al, Nosocomial infections in combined medical-surgical intensive care units in the United States[J]. Infect Control Hosp Epidemiol,2000, 21(8):510-515.
  • 10Clinical and Laboratory Standards Institute. Performance standards for antimierobial susceptibility testing[S]. Fifteenth informational supplement. M100-S15. CLSI,2005.

共引文献70

同被引文献114

引证文献14

二级引证文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部